Drug maker tracks Kids' arthritis treatment experience
NCT ID NCT05754710
Summary
This study is monitoring children aged 2-18 who are already taking Xeljanz for juvenile arthritis in routine Korean medical practice. Researchers will track their treatment experience for up to 44 weeks to understand the drug's safety and effectiveness in real-world use. This is a required safety monitoring study after the drug's approval, not a test of new treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.